The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

Medical science has long been on the hunt for a deeper understanding of the devastating scarring of the body's organs known ...

IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...

A research group from Ningbo Institute of Materials Technology and Engineering (NIMTE) of the Chinese Academy of Sciences ...

Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of ...

Leerink Partners analyst Faisal Khurshid has maintained their bullish stance on PLRX stock, giving a Buy rating on September 13. Faisal ...

Findings of a systematic review highlight the need for standardized assessment tools and targeted treatments for chronic ...

Living with IPF has brought many emotional ups and downs for columnist Sam Kirton, and recent events have caused him to hit ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

Among patients with PPF, those treated with 60 mg of admilparant showed significant decreases in periostin, ferritin, and ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute ...

4,5 Nerandomilast (BI 1015550) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for idiopathic pulmonary fibrosis (IPF) ...